Acute Decompensated Heart Failure

Hammond, Drayton A.; Smith, Melanie; Lee, Kristen C.; Honein, Danielle; Quidley, April Miller

doi:10.1177/0885066616669494

Cited by 9 publications

(6 citation statements)

References 97 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some mechanisms can be proposed, such as systemic infection effects on HF haemodynamics and mechanisms related to COVID‐19. Infection is a common cause of acute DHF (ADHF) 5 . Pulmonary infection was one of the most prevalent factors precipitating ADHF and was reported to be independently associated with hospital mortality 6,7 .…”

Section: Discussionmentioning

confidence: 99%

“…Infection is a common cause of acute DHF (ADHF). 5 Pulmonary infection was one of the most prevalent factors precipitating ADHF and was reported to be independently associated with hospital mortality. 6,7 Although the exact cause is still unclear, activation of inflammatory and immunological pathways may lead to systemic effects and myocardial dysfunction.…”

Section: Laboratory Datamentioning

confidence: 99%

See 1 more Smart Citation

Worsening of heart failure by coronavirus disease 2019 is associated with high mortality

et al. 2021

View full text Add to dashboard Cite

Aims Patients with advanced heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) and concurrent coronavirus disease 2019 (COVID-19) might have a higher risk of severe events. Methods and results We retrospectively studied 16 patients with advanced HFrEF who developed COVID-19 between 1 March and 29 May 2020. Follow-up lasted until 30 September. Ten patients previously hospitalized with decompensated HFrEF were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during hospitalization. Six patients undergoing ambulatory care at initiation of COVID-19 symptoms were hospitalized because of advanced HFrEF. All patients who experienced worsening of HFrEF due to COVID-19 required higher doses or introduction of additional inotropic drugs or intra-aortic balloon pump in the intensive care unit. The mean intravenous dobutamine dose before SARS-CoV-2 infection in previously hospitalized patients (n = 10) and the median (inter-quartile range) peak intravenous dobutamine dose during SARS-CoV-2 infection in all patients (n = 16) were 2 (0-7) μg/kg/min and 20 (14-20) (P < 0.001), respectively. During follow-up, 56% underwent heart transplantation (n = 2) or died (n = 7). Four patients died during hospitalization from mixed shock consequent to severe acute respiratory syndrome with inflammatory storm syndrome associated with septic and cardiogenic shock during COVID-19. After COVID-19 recovery, two patients died from mixed septic and cardiogenic shock and one from sustained ventricular tachycardia and cardiogenic shock. Five patients were discharged from hospital to ambulatory care. Four were awaiting heart transplantation. Conclusion Worsening of advanced HF by COVID-19 is associated with high mortality. This report highlights the importance of preventing COVID-19 in patients with advanced HF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Laboratory Datamentioning

confidence: 99%

Worsening of heart failure by coronavirus disease 2019 is associated with high mortality

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Additional potential usage of SGLT2i may be anticipated for the treatment of acute HF (AHF), which is the major cause of HHF, and for which there are no currently available therapies that improve clinical outcomes [96]. The EMPA Acute Heart Failure, EMPAG-HF and EMPULSE trials are underway to study the effects of SGLT2i on clinical outcomes in the AHF population (ClinicalTrials.gov Identifiers: NCT03554200, NCT04049045 and NCT04157751, respectively), while the EMPA-RESPONSE study has been published recently [97].…”

Section: Unmet Medical Needs and Conclusionmentioning

confidence: 99%

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Brito

Bettencourt

Carvalho

et al. 2020

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and cardiovascular mortality. These benefits appear to be independent of glycaemic control and have recently been demonstrated in the HF population with reduced ejection fraction (HFrEF), with or without T2D. This comprehensive, evidence-based review focuses on the published studies concerning HF outcomes with SGLT2i, discussing issues that may underlie the different results, along with the impact of these new drugs in clinical practice. The potential translational mechanisms behind SGLT2i cardio-renal benefits and the information that ongoing studies may add to the already existing body of evidence are also reviewed. Finally, we focus on practical management issues regarding SGLT2i use in association with other T2D and HFrEF common pharmacological therapies. Safety considerations are also highlighted. Considering the paradigm shift in T2D management, from a focus on glycaemic control to a broader approach on cardiovascular protection and event reduction, including the potential for wide SGLT2i implementation in HF patients, with or without T2D, we are facing a promising time for major changes in the global management of cardiovascular disease.

show abstract

“…Acute decompensated heart failure (ADHF) refers to the acute attack of symptoms and signs of HF [2]. The common causes of ADHF include drug and dietary disorders, arrhythmia, deterioration of renal function, poor control of hypertension, myocardial infarction, and infection [3]. Risk of readmission within 6 months was as high as 50% for ADHF patients hospitalized due to worsening HF [4], and repeated hospitalization will seriously affect the quality of life of ADHF patients.…”

Section: Introductionmentioning

confidence: 99%

Update on the Value of Lung Ultrasound Examination in Acute Decompensated Heart Failure Patients with Various Left Ventricular Ejection Fraction

Zhang¹,

Zhu²,

Li³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Acute decompensated heart failure (ADHF) is one of the most common causes of hospital admission for cardiovascular diseases. ADHF often affects the elderly population, is associated with high morbidity, admission rate and mortality. Pulmonary congestion (PC) is the most common cause of hospitalization among ADHF patients. Previous studies have shown that lung ultrasound (LUS) serves as a valuable tool for the evaluation of PC in patients with heart failure in terms of diagnosis, guiding of the treatment, and post-discharge monitoring. The use of LUS for ADHF is well described and already widely used in the daily clinical practice. PC might differ in ADHF patients with different left ventricular ejection fraction value and treatment options should be steadily adjusted according to the LUS-derived PC results to improve the outcome. This review summarized the value of LUS examination in patients with ADHF with preserved, mildly reduced, and reduced left ventricular ejection fraction, aiming to expand the rational use of LUS, promote the LUS-guided management and improve the outcome among patients with ADHF.

show abstract

Acute Decompensated Heart Failure

Cited by 9 publications

References 97 publications

Worsening of heart failure by coronavirus disease 2019 is associated with high mortality

Worsening of heart failure by coronavirus disease 2019 is associated with high mortality

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Update on the Value of Lung Ultrasound Examination in Acute Decompensated Heart Failure Patients with Various Left Ventricular Ejection Fraction

Contact Info

Product

Resources

About